4//SEC Filing
Rosett Max 4
Accession 0001415889-24-023809
CIK 0001472012other
Filed
Sep 19, 8:00 PM ET
Accepted
Sep 20, 7:26 PM ET
Size
9.1 KB
Accession
0001415889-24-023809
Insider Transaction Report
Form 4
Immunome Inc.IMNM
Rosett Max
Chief Financial Officer
Transactions
- Sale
Common Stock
2024-09-19$16.01/sh−14,380$230,224→ 47,476 total - Exercise/Conversion
Common Stock
2024-09-19$1.05/sh+42,000$44,100→ 61,856 total - Exercise/Conversion
Stock option (right to buy)
2024-09-19−42,000→ 91,848 totalExercise: $1.05Exp: 2033-03-22→ Common Stock (42,000 underlying)
Footnotes (4)
- [F1]The shares were sold pursuant to sell to cover transactions.
- [F2]The weighted average sale price for the transaction report was $16.01, and the range of prices were between $15.97 and $16.10. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.
- [F3]The Reporting Person's Form 3 filed on October 12, 2023 contains a scrivener's error reflecting an exercise price of $1.06 instead of the correct exercise price of $1.05.
- [F4]25% of the shares vested on March 24, 2023, and the remaining shares shall vest in 36 monthly installments thereafter.
Documents
Issuer
Immunome Inc.
CIK 0001472012
Entity typeother
Related Parties
1- filerCIK 0001994071
Filing Metadata
- Form type
- 4
- Filed
- Sep 19, 8:00 PM ET
- Accepted
- Sep 20, 7:26 PM ET
- Size
- 9.1 KB